All In Biotech

Drug Trial Radar · NCT07197307

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 31, 2025

Primary completion

Apr 30, 2030

Study completion Apr 30, 2030

Sponsor

Lead sponsor
Universität MünsterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie; Sobi, Inc.
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.

Conditions

  • Aggressive Diffuse Large B-cell Lymphoma
  • High-grade B-cell Lymphoma (HGBL)
  • Follicular Lymphoma (FL) Grade 3B

Interventions

  • Loncastuximab Tesirine and EpcoritamabDrug

    Loncastuximab tesirine: Loncastuximab tesirine 150 µg/kg iv for 2 cycles followed by 75 µg/kg iv on day 1 of each 21-day cycle in responding patients for 4 cycles subsequently (max. 6 cycles). Epcoritamab: Step-up dosing for epcoritamab sc will be performed, consisting of a 0.16 mg sc priming dose on day 1 of cycle 1 (day 8 of cycle 1 for loncastuximab tesirine), followed by a 0.8 mg sc dose on day 8, and full dosing with 48 mg sc on day 15. Starting from day 15, epcoritamab will be administered weekly during cycle 2-3, then once every 2 weeks during cycle 4-9, and once every 4 weeks from cycle 10 until cycle 13 (max. 13 cycles).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best overall response rate (BORR)Time frame: 12 months after the start of study therapy

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Universitaetsklinikum Aachen

    Aachen, Germany · Recruiting

  • Universitaetsklinikum Augsburg

    Augsburg, Germany · Recruiting

  • Vivantes Netzwerk fuer Gesundheit

    Berlin, Germany · Recruiting

  • Charite Universitaetsmedizin Berlin

    Berlin, Germany · Recruiting

  • HELIOS Klinikum Berlin-Buch

    Berlin, Germany · Recruiting

  • Evangelisches Klinikum Bethel

    Bielefeld, Germany · Recruiting

  • Klinikum Chemnitz

    Chemnitz, Germany · Recruiting

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, Germany · Recruiting

  • Universitaetsklinikum Erlangen

    Erlangen, Germany · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Not yet recruiting

  • Universitaetsklinikum Frankfurt

    Frankfurt, Germany · Recruiting

  • Medical Center - University Of Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • Universitaetsmedizin Greifswald

    Greifswald, Germany · Recruiting

  • Universitaetsklinikum Halle (Saale)

    Halle, Germany · Recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg, Germany · Not yet recruiting

  • St. Barbara-Klinik Hamm

    Hamm, Germany · Recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Universitaet Des Saarlandes

    Homburg, Germany · Recruiting

  • Universitaetsklinikum Jena

    Jena, Germany · Recruiting

  • Staedtisches Klinikum Karlsruhe

    Karlsruhe, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein

    Kiel, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein

    Lübeck, Germany · Recruiting

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Germany · Recruiting

  • Philipps-Universitaet Marburg

    Marburg, Germany · Recruiting

  • Muehlenkreiskliniken

    Minden, Germany · Recruiting

  • Klinikum der Universitaet Muenchen

    München, Germany · Not yet recruiting

  • Universitätsklinikum Münster, Medizinische Klinik A

    Münster, Germany · Recruiting

  • Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts

    Mutlangen, Germany · Recruiting

  • Ortenau Klinikum

    Offenburg, Germany · Recruiting

  • Klinikum Oldenburg

    Oldenburg, Germany · Recruiting

  • Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn

    Paderborn, Germany · Recruiting

  • Universitaetsklinikum Regensburg

    Regensburg, Germany · Recruiting

  • Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe

    Stuttgart, Germany · Not yet recruiting

  • Universitaetsklinikum Ulm

    Ulm, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.